Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

AI in life sciences raises various patent law considerations, including subject matter eligibility, novelty/obviousness, and sufficiency of disclosure, explains patent attorney Noah K. Tilton.

XOMA Royalty’s CEO Owen Hughes and CIO Brad Sitko explain how royalty investing mitigates risks while expediting biotech drug development.